<DOC>
	<DOCNO>NCT02501200</DOCNO>
	<brief_summary>A randomized , open-label , 2-way crossover study compare pharmacokinetics safety CKD-391 coadministration Atorvastatin Ezetimibe health volunteer .</brief_summary>
	<brief_title>CKD-391 Pharmacokinetic Study Phase I</brief_title>
	<detailed_description>To compare CKD-391 ( Experimental product ) dose Atorvastatin calcium Ezetimibe combination health male subject purpose trial . Following evaluated trial ; Characteristics safety/Tolerability Of CKD-391 .</detailed_description>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Bwt &gt; =50kg , BMI 18.5~25 sign inform consent form prior study participation Clinically significant disease Subject sign symptom acute disease within 28 day start administration investigational drug Clinically significant allergic disease Impossible take institutional standard meal Previously donate whole blood within 60 day component blood within 20 day Previously participate trial within 90 day Continued take caffeine ( caffeine &gt; 5 cup/day ) , drink ( alcohol &gt; 30 g/day ) stop drinking severe heavy smoker ( cigarette &gt; 10 cigarette per day ) clinical trial An impossible one participate clinical trial investigator 's decision include laboratory test result</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Dyslipidemia</keyword>
	<keyword>CKD-391</keyword>
	<keyword>Atorvastatin</keyword>
	<keyword>Ezetimibe</keyword>
</DOC>